Skip to Content

Catalyst Pharmaceuticals Inc CPRX

Morningstar Rating
$16.90 −0.09 (0.53%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CPRX is trading at a 682% premium.
Price
$16.83
Fair Value
$21.29
Uncertainty
High
1-Star Price
$74.31
5-Star Price
$32.18
Economic Moat
Yvvm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CPRX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$16.99
Day Range
$16.7517.24
52-Week Range
$11.5517.50
Bid/Ask
$16.25 / $17.40
Market Cap
$2.00 Bil
Volume/Avg
3 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
31.38
Price/Sales
4.77
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
167

Comparables

Valuation

Metric
CPRX
VNDA
ACAD
Price/Earnings (Normalized)
31.3879.0359.73
Price/Book Value
3.550.676.52
Price/Sales
4.772.023.72
Price/Cash Flow
10.6881.9444.43
Price/Earnings
CPRX
VNDA
ACAD

Financial Strength

Metric
CPRX
VNDA
ACAD
Quick Ratio
4.664.621.73
Current Ratio
5.094.712.04
Interest Coverage
Quick Ratio
CPRX
VNDA
ACAD

Profitability

Metric
CPRX
VNDA
ACAD
Return on Assets (Normalized)
46.85%0.87%7.16%
Return on Equity (Normalized)
55.59%1.03%12.48%
Return on Invested Capital (Normalized)
55.09%1.02%7.68%
Return on Assets
CPRX
VNDA
ACAD
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
PxhdysnwjWtkm$598.1 Bil
Vertex Pharmaceuticals Inc
VRTX
VqhkxlvTqylsj$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
SlrmkgrKjwcyx$119.6 Bil
Moderna Inc
MRNA
LnwfsxcBwjn$47.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
SnfhnbhlrQhmryy$30.4 Bil
argenx SE ADR
ARGX
KkfxvxncHdxtb$27.4 Bil
BioNTech SE ADR
BNTX
QbytmkxxdVbbn$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
GmtzpgfQmckng$16.1 Bil
United Therapeutics Corp
UTHR
JfcfrwkgFfjq$14.7 Bil
Incyte Corp
INCY
BmqxjhykdYylhm$12.9 Bil

Sponsor Center